Special Issue "Pharmacogenomics of Heart, Kidney and Autoimmune Disease"

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Pharmacogenetics".

Deadline for manuscript submissions: closed (10 April 2023) | Viewed by 407

Special Issue Editor

Department of Clinical Pharmacy, School of Pharmacy, Taipei Medical University, Taipei 110, Taiwan
Interests: pharmacogenetics; pharmacy; pharmacogenomics; personalized therapy; calcium channel related genes

Special Issue Information

Dear Colleagues, 

The technology of next-generation sequencing (NGS) has led to large-scale genetic variant identification, which reveals the mechanisms of how genes affect an individual’s response to drugs and how to select effective therapeutic drugs. Furthermore, recent advances in genome-wide association study (GWAS), immunogenomics (T cell sequencing, B cell sequencing), and single-cell sequencing enables us to use a high-resolution approach to understand the complex interplay between genotype and phenotype. In this Special Issue on “Pharmacogenomics of Heart Disease and Autoimmune Disease”, we would like to invite scientists in pharmacogenomics, immunogenomics, bioinformatics, and/or integrative genomics to discuss heart disease (coronary heart disease, heart attack, congestive heart failure, congenital heart disease, and marfan syndrome), autoimmune disease (Graves’ disease, inflammatory bowel disease, multiple sclerosis, psoriasis, rheumatoid arthritis, ankylosing spondylitis), kidney disease (acute kidney injury, chronic kidney disease, kidney transplant), and future perspectives. Our aim is for this collection of pharmacogenomics articles to attract readers’ interest and contribute to the advancement of knowledge in personalized medicine.

Prof. Dr. Wei-Chiao Chang
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • pharmacogenomics
  • immunogenomics
  • bioinformatics
  • integrative genomics
  • heart disease
  • autoimmune disease
  • kidney disease

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop